[1]罗曼,陈晓隆.新生血管性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物治疗进展[J].眼科新进展,2020,40(6):582-586.[doi:10.13389/j.cnki.rao.2020.0134]
　LUO Man,CHEN Xiaolong.Progress in treatment of neovascular age-related macular degeneration with intravitreal injection of anti-VEGF drugs[J].Recent Advances in Ophthalmology,2020,40(6):582-586.[doi:10.13389/j.cnki.rao.2020.0134]
点击复制

新生血管性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物治疗进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年6期
页码:
582-586
栏目:
文献综述
出版日期:
2020-06-05

文章信息/Info

Title:
Progress in treatment of neovascular age-related macular degeneration with intravitreal injection of anti-VEGF drugs
作者:
罗曼; 陈晓隆
110004　辽宁省沈阳市,中国医科大学附属盛京医院眼科
Author(s):
LUO Man; CHEN Xiaolong
Department of Ophthalmology,Shengjing Hospital of China Medical University,Shenyang 110004,Liaoning Province,China
关键词:
新生血管性年龄相关性黄斑变性; 抗血管内皮生长因子; 临床治疗
Keywords:
neovascular age-related macular degeneration;  anti-VEGF;  clinical treatment
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2020.0134
文献标志码:
A
摘要:
年龄相关性黄斑变性是引起50岁以上人群视力不可逆性损伤的主要原因之一，新生血管性年龄相关性黄斑变性（neovascular age-related macular degeneration,nAMD）也称湿性年龄相关性黄斑变性（wet age-related macular degeneration,wAMD），是其晚期阶段，可导致最严重的视力丧失。血管内皮生长因子（vascular endothelial growth factor,VEGF）是脉络膜新生血管和视网膜渗漏形成的主要因素，抗VEGF治疗是目前唯一实现多数患者视力改善并且停止疾病进展的治疗方法，因此玻璃体内注射抗VEGF药物已经成为wAMD一线治疗方法。用于临床治疗wAMD的抗VEGF药物主要有哌加他尼、贝伐单抗、雷珠单抗、阿柏西普和康柏西普。治疗方案有固定式、按需式以及治疗和延长式治疗方案。Brolucizumab和abicipar pegol是2种新的抗VEGF药物，正处于3期临床试验阶段。本文对以上药物治疗wAMD的研究进展进行综述。
Abstract:
Age-related macular degeneration (AMD) is considered one of the main causes of irreversible vision loss in populations over 50 year-old. Wet age-related macular degeneration (wAMD), known as the neovascular age-related macular degeneration (nAMD) is an advanced stage, which is responsible for the most severe vision loss. Vascular endothelial growth factor (VEGF) is the main factor that leads to the development of choroidal neovascularization and retinal leakage. At present, anti-VEGF therapy is the only treatment that achieves vision gains in many patients and halts progression in most of them, and intravitreal injection of anti-VEGF drugs has become the first-line treatment of wAMD. The anti-VEGF drugs used in clinical treatment of wAMD mainly include Pegaptanib, Bevacizumab, Ranibizumab, Aflibercept and Conbercept, and the treatment regimens include fixed, on-demand, and treat-and-extend therapy. Brolucizumab and abicipar pegol, two new anti-VEGF drugs, are undergoing phase 3 clinical trials. The article summaries the research progress of above drugs for the treatment of wAMD.

参考文献/References:

［1］　中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会.中国老年性黄斑变性临床诊断治疗路径［J］.中华眼底病杂志,2013,29(4):343-355.
Ocular Fundus Diseases Society,Chinese Ophthalmological Society,Chinese Medical Association.The clinical guideline and clinical pathway development committee of age-related macular degeneration［J］.Chin J Ocul Fundus Dis,2013,29(4):343-355.
［2］　CUI C,LU H.Clinical observations on the use of new anti-VEGF drug,conbercept,in age-related macular degeneration therapy:A meta-analysis［J］.Clin Interv Aging,2018,13:51-62.
［3］　WONG W L,SU X,LI X,CHEUNG C M,KLEIN R,CHENG C Y,et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:a systematic review and meta-analysis［J］.Lancet Glob Health,2014,2(2):106-116.
［4］　NIKKHAH H,KARIMI S,AHMADIEH H,AZARMIA M,ABRISHAMI M,AHOOR H,et al.Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases:clinical practice guideline［J］.J Ophthalmic Vis Res,2018,13(2):158-169.
［5］　FERRIS F L,WILKINSON C P,BIRD A,CHAKRAVARTHY U,CHEW E,CSAKY K,et al.Clinical classification of age-related macular degeneration［J］.Ophthalmology,2013,120(4):844-851.
［6］　BIRD A C,BRESSLER N M,BRESSLER S B,CHISHOLM I H,COSCAS G,DAVIS M D,et al.An international classification and grading system for age-related maculopathy and age-related macular degeneration.The international ARM epidemiological Study Group［J］.Surv Ophthalmol,1995,39(5):367-374.
［7］　Age-Related Eye Disease Study Research Group.The age-related eye disease study system for classifying age-related macular degeneration from stereoscopic color fundus photographs:the age-related eye disease study report number 6［J］.Am J Ophthalmol,2001,132(5):668-681.
［8］　LIU K,XIE B.Today and future of age-related macular degeneration［J］.ISRN Ophthalmol,2012,2012:480212.
［9］　SZABO S M,HEDEGAAR M,CHAN K,THORLUND K,CHRISTENSEN R,VORUM H,et al.Ranibizumab vs.aflibercept for wet age-related macular degeneration:network meta-analysis to understand the value of reduced frequency dosing［J］.Curr Med Res Opin,2015,31(11):2031-2042.
［10］　INOUE M,KADONOSONO K,ARAKAWA A,YAMANE S,ISHIBASHI T.Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration［J］.Jpn J Ophthalmol,2015,59(3):173-178.
［11］　BAKRI S J,THORNE J E,HO A C,EHLERS J P,SCHOENBERGER S D,YEH S,et al.Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration［J］.Ophthalmology,2019,26(1):55-63.
［12］　NGUYEN C L,OH L J,WONG E,WEI J,CHILOV M.Anti-vascular endothelial growth factor for neovascular age-related macular degeneration:a meta-analysis of randomized controlled trials［J］.BMC Ophthalmol,2018,18(1):130.
［13］　FERRARA N.Vascular endothelial growth factor and age-related macular degeneration:from basic science to therapy［J］.Nat Med,2010,16(10):1107-1111.
［14］　BASILE A S,HUTMACHER M M,KOWALSKI K G,GANDELMAN K Y,NICKENS D J.Population pharmacokinetics of pegaptanib sodium (Macugen?) in patients with diabetic macular edema［J］.Clin Ophthalmol,2015,9:323-335.
［15］　D’AMICO D J,MASONSON H N,PATEL M,ADAMIS A P,CUNNINGHAM E T,GUYER D R,et al.Pegaptanib sodium for neovascular age-related macular degeneration:two-year safety results of the two prospective,multicenter,controlled clinical trials［J］.Ophthalmology,2006,113(6):992-1001.
［16］　ISHIBASHI T.Maintenance therapy with pegaptanib sodium for neovascular age-macular degeneration:an exploratory study in Japanese patients (LEVEL-J study)［J］.Jpn J Ophthalmol,2013,57(5):417-423.
［17］　CHAKRAVARTHY U,ADAMIS A P,CUNNINGHAM E T,GOLDBAUM M,GUYER D R,KATZ B,et al.Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration［J］.Ophthalmology,2006,113(9):1508.
［18］　AFARID M,SADEGI S A,RAHAT F,RAHAT F,AZIMI A.Intravitreal injection of Bevacizumab:review of our previous experience［J］.Iran J Pharm Res,2018,17(3):1093-1098.
［19］　TUFAIL A,PATEL P J,EGAN C,HYKIN P,DA CRUZ L,GREGOR Z,et al.Bevacizumab for neovascular age related macular degeneration (ABC Trial):multicentre randomised double masked study［J］.BMJ,2010,340:c2459.
［20］　MODARRES M,NASERIPOUR M,FALAVARJANI K G,NIKEGHBALI A,HASHEMI M,PARVARESH M M,et al.Intravitreal injection of 2.5 mg versus 1.25 mg (Avastin) for treatment of CNV associated with AMD［J］.Retina,2009,29(3):319-324.
［21］　MARTIN D F,MAGUIRE M G,FINE S L,YING G S,JAFFE G J,GRUNWALD J E,et al.Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration:two-year results［J］.Ophthalmology,2012,119(7):1388-1398.
［22］　JOHNSTON R L,CARIUS H J,SKELLY A,FERREIRA A,MILNES F,MITCHELL P.A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom［J］.Adv Ther,2017,34(3):703-712.
［23］　ROSENFELD P J,BROWN D M,HEIER J S,BOYER D S,KAISER P K,CHUNG C Y,et al.Ranibizumab for neovascular age-related macular degeneration［J］.N Engl J Med,2006,355(14):1419-1431.
［24］　BROWN D M,KAISER P K,MICHELS M,SOUBRANE G,HEIER J S,KIM R Y,et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration［J］.N Engl J Med,2006,355(14):1432-1444.
［25］　ABRAHAM P,YUE H,WILSON L.Randomized,double-masked,sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER study year 2［J］.Am J Ophthalmol,2010,150(3):315-324.
［26］　SINGER M A,AWH C C,SADDA S,FREEMAN W R,ANTOSZYK A N,WONG P,et al.Horizon:an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration［J］.Ophthalmology,2012,119(6):1175-1183.
［27］　ROFAGHA S,BHISITKUL R B,BOYER D S,SADDA S R,ZHANG K.Seven-year outcomes in ranibizumab-treated patients in ANCHOR,MARINA,and HORIZON:a multicenter cohort study (SEVEN-UP)［J］.Ophthalmology,2013,120(11):2292-2299.
［28］　HOLZ F G,AMOAKU W,DONATE J,GUYMER R H,KELLNER U,SCHLINGEMANN R O,et al.Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration:the SUSTAIN study［J］.Ophthalmology,2011,118(4):663-671.
［29］　GUO M Y,CHENG J,ETMINAN M,ZAFARI Z,MABERLEY D.One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration:a meta-analysis［J］.Acta Ophthalmol,2019,97(1):e1-e7.
［30］　PAPADOPOULOS N,MARTIN J,RUAN Q,RAFIQUE A,ROSCONI M P,SHI E,et al.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap,ranibizumab and bevacizumab［J］.Angiogenesis,2012,15(2):171-185.
［31］　OGURA Y,TERASAKI H,GOMI F,YUZAWA M,IIDA T,HONDA M,et al.Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration:outcomes in the Japanese subgroup of the VIEW 2 study［J］.Br J Ophthalmol,2015,99(1):92-97.
［32］　SCHMIDT-ERFURTH U,KAISER P K,KOROBELNIK J F,BROWN D M,CHONG V,NGUYEN Q D,et al.Intravitreal aflibercept injection for neovascular age-related macular degeneration:ninety-six-week results of the VIEW studies［J］.Ophthalmology,2014,121(1):193-201.
［33］　ZHANG M,ZHANG J,YAN M,LUO D,ZHU W,KAISER P K,et al.A phase 1 study of KH902,a vascular endothelial growth factor receptor decoy,for exudative age-related macular degeneration［J］.Ophthalmology,2011,118(4):672-678.
［34］　LI X,XU G,WANG Y,XU X,LIU X,TANG S,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study［J］.Ophthalmology,2014,121(9):1740-1747.
［35］　LIU K,SONG Y,XU G,YE J,WU Z,LIU X,et al.Conbercept for treatment of neovascular age-related macular degeneration:results of the randomized phase 3 PHOENIX study［J］.Am J Ophthalmol,2019,197:156-167.
［36］　ZHANG J,LIANG Y,XIE J,LI D,HU Q,LI X,et al.Conbercept for patients with age-related macular degeneration:a systematic review［J］.BMC Ophthalmol,2018,18(1):142.
［37］　FUNG A E,LALWANI G A,ROSENFELD P J,DUBOVY S R,MICHELS S,FEUER W J,et al.An optical coherence tomography-guided,variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration［J］.Am J Ophthalmol,2007,143(4):566-683.
［38］　ABEDI F,WICKREMASHMASHINGHE S,ISLAM A F,INGLIS K M,GUYMER R H.Anti-VEGF treatment in neovascular age-related macular degeneration:a treat-and-extend protocol over 2 years［J］.Retina,2014,34(8):1531-1538.
［39］　AL-ZAMIL W M,YASSIN S A.Recent developments in age-related macular degeneration:a review［J］.Clin Interv Aging,2017,12:1313-1330.
［40］　BAHADORANI S,SINGER M.Recent advances in the management and understanding of macular degeneration［J］.F1000Res,2017,6:519.
［41］　SOUIED E H,DEVIN F,MAUGET-FAYSSE M,KOLAR P,WOLF-SCHNURRBUSCH U,FRAMME C,et al.Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor:a phase I/II study［J］.Am J Ophthalmol,2014,158(4):724-732.
［42］　CALLANAN D,KUNIMOTO D,MATURI R K,PATEL S S,STAURENGHI G,WOLF S,et al.Double-masked,randomized,phase 2 evaluation of Abicipar Pegol (an anti-VEGF DARPin therapeutic) in neovascular age-related macular degeneration［J］.J Ocul Pharmacol Ther,2018,34(10):700-709.
［43］　HOLZ F G,DUGEL P U,WEISSGERBER G,HAMILTON R,SOLVA R,BANDELLO F,et al.Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration:A randomized controlled study［J］.Ophthalmology,2016,123(5):1080-1089.
［44］　DUGEL P U,JAFFE G J,SALLSTIG P,WARBURTON J,WEICHSELBERGER A,WIELAND M,et al.Brolucizumab versus Aflibercept in participants with neovascular age-related macular degeneration: a randomized trial［J］.Ophthalmology,2017,124(9):1296-1304.

相似文献/References:

[1]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[2]刘李平 宋徽 肖云 曹小鹏 白润 陈珍.玻璃体注射雷珠单抗治疗缺血型视网膜中央静脉阻塞的临床观察[J].眼科新进展,2013,33(11):000.
[3]刘晶晶,刘子扬,彭清.渗出型年龄相关性黄斑变性的抗血管内皮生长因子治疗进展[J].眼科新进展,2015,35(1):084.[doi:10.13389/j.cnki.rao.2015.0024]
　LIU Jing-Jing,LIU Zi-Yang,PENG Qing.Recent advances in anti-vascular endothelial growth factor for exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(6):084.[doi:10.13389/j.cnki.rao.2015.0024]
[4]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
　XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(6):1093.[doi:10.13389/j.cnki.rao.2016.0292]
[5]李松峰,邓光达,刘敬花,等.视网膜下液引流联合玻璃体内注射抗血管内皮生长因子药物治疗重度渗出性视网膜脱离Coats病的临床疗效[J].眼科新进展,2017,37(6):569.[doi:10.13389/j.cnki.rao.2017.0144]
　LI Song-Feng,DENG Guang-Da,LIU Jing-Hua,et al.Subretinal fluid drainage combined with intravitreal injection of anti-vascular endothelial growth factor in treatment of severe exudative retinal detachment Coats disease[J].Recent Advances in Ophthalmology,2017,37(6):569.[doi:10.13389/j.cnki.rao.2017.0144]
[6]吕亚男,宫媛媛.抗血管内皮生长因子（VEGF）治疗与视网膜下纤维化研究进展[J].眼科新进展,2017,37(6):583.[doi:10.13389/j.cnki.rao.2017.0148]
　LV Ya-Nan,GONG Yuan-Yuan.Anti-VEGF therapy and subretinal fibrosis[J].Recent Advances in Ophthalmology,2017,37(6):583.[doi:10.13389/j.cnki.rao.2017.0148]
[7]邵毅.阿柏西普治疗新生血管性年龄相关性黄斑变性——2017欧洲视网膜专家学会共识解读[J].眼科新进展,2018,38(7):601.[doi:10.13389/j.cnki.rao.2018.0142]
　SHAO Yi.Aflibercept treatment for neovascular age related macular degeneration—The Interpretation of The Consensus of European Society of Retina Specialists，2017[J].Recent Advances in Ophthalmology,2018,38(6):601.[doi:10.13389/j.cnki.rao.2018.0142]
[8]许晓璇,胡裕翔,程艺,等.早产儿视网膜病变抗血管内皮生长因子药物治疗新进展[J].眼科新进展,2018,38(9):883.[doi:10.13389/j.cnki.rao.2018.0209]
　XU Xiao-Xuan,HU Yu-Xiang,CHENG Yi,et al.New advances in anti-vascular endothelial growth factor drug therapy for retinopathy of prematurity[J].Recent Advances in Ophthalmology,2018,38(6):883.[doi:10.13389/j.cnki.rao.2018.0209]
[9]朱婷婷,王权,姜彩辉.糖尿病黄斑水肿治疗新进展[J].眼科新进展,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]
　ZHU Ting-Ting,WANG Quan,JIANG Cai-Hui.Recent research advances in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(6):296.[doi:10.13389/j.cnki.rao.2019.0067]
[10]宋晶,熊杰.康柏西普玻璃体内注射治疗特发性脉络膜新生血管[J].眼科新进展,2020,40(2):169.[doi:10.13389/j.cnki.rao.2020.0040]
　SONG Jing,XIONG Jie.Intravitreal injection of Conbercept in treatment of patients with idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(6):169.[doi:10.13389/j.cnki.rao.2020.0040]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-06-05